Cure Ventures is a venture capital firm focusing on company formation around groundbreaking curative technologies.

Cure Ventures harnesses our team's skills and decades of company-building experience to create innovative companies that aim to eradicate diseases by focusing on de novo company formation built around bold ideas and visionary entrepreneurs. 

We provide the right level of human and financial capital that is required at each stage of the company's life. We seek to build great companies around pioneering scientific solutions with strong intellectual property positions. The Cure Ventures team focuses on disruptive technologies that target high unmet patient needs.

The optimal company build will exhibit a clear genetic validation, substantiated and rigorously derived scientific data, the provenance of a distinguished scientific laboratory, biology with mechanistic clarity, multiple commercial applications, large uncrowded markets, expedited clinical routes, string partnering interest from large pharmaceutical companies, and an articulable oath to an exit.

Cure Ventures

Cure Ventures is proud to call #Boston home to our newly launched #venturecapital firm. We recently talked with Jonathan Saltzman at Boston Globe Media about our plans to help build new #lifescience and #biotech companies, some of which may be in the Boston area! Read the full article below:

Our founding partners recently sat down with Brian Gormley at The Wall Street Journal to discuss Cure Ventures’ inaugural fund launch and our team’s unique investment approach. Read the full article below. #venturecapital #lifescience #boston

Today we announced the close at the targeted hard cap of $350 million for our inaugural fund. The fund is led by managing partners Richard Lim, David Fallace, and Lou Tartaglia and will build new life science and biotech companies, primarily focused on the development of innovative and impactful therapeutics.
 
Our unique approach embraces genetic validation as part of an iterative process to guide a drug through development, increasing the probability of success and mitigating the cost of failure. Embedded Cure operators will work alongside portfolio company founders to drive day-to-day decision making. We leverage a seed funding model, allowing for important de-risking activities and setting companies up for success in the clinic and beyond. 
 
We founded Cure with a grand ambition: to eradicate life-debilitating and life-ending diseases with curative technologies. We know it is people who drive the development of therapeutics that change patients’ lives, not capital. This is why we are committed to continuously interrogating and validating technology to find the best path forward in collaboration with founders.

Read the press release here: https://lnkd.in/g6hDShiX

#venturecapital #lifescience #biotech

BioNTech SE is a biotechnology company that focuses on developing mRNA-based vaccines and therapies for various diseases, including infectious diseases and cancer.

BioNTech SE

Moderna, Inc. is a biotechnology company specializing in mRNA technology to develop vaccines and therapeutics for infectious diseases, immuno-oncology, and rare diseases.

Moderna, Inc.

Translate Bio, Inc. is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

Translate Bio, Inc.

CureVac AG is a biopharmaceutical company that specializes in the development of mRNA-based vaccines and therapies. The company focuses on leveraging its proprietary mRNA technology to address various diseases, including oncological and infectious diseases, as well as rare diseases.

CureVac AG

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 15, 2024 9:19 AM	f60de2d3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	988a61c4
crunchbase profile	general
li profile	general	May 15, 2024 9:19 AM	ff85b9f5
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CUREVC

CureVac AG